• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    T

    Texas Oncology

    EST. 1999
    510论文总数
    6,479引用总数

    .

    论文量&引用量时间轴

    机构学者

    论文(510)

    年份
    起
    –
    止
    排序
    1Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.
    Joshua E Reuss,Lyudmila Bazhenova, Nofisat Ismaila,Fawzi Abu Rous, Amith Ahluwalia, Krishna Alluri, Ibrahim Hanna Azar,Toby Campbell, Greg Durm,Jill Feldman,Narjust Florez, Janet Freeman-Daily,

    PURPOSE:To provide evidence-based recommendations for patients with stage IV non-small cell lung cancer with driver alterations. METHODS:This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS:This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Thirteen studies were identified in the latest search of literature to date. RECOMMENDATIONS:Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients with driver alterations.Additional information is available at www.asco.org/thoracic-cancer-guidelines.

    2026Journal of clinical oncology official journal of the American Society of Clinical Oncology(2026)引用:7
    引用
    AI阅读
    加入学术空间
    2ARTEMIDE-Gastric01: A Phase 3 Randomized Study of Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan (T-Dxd) As First-Line (1L) Treatment for Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Cancer (GC/GEJC).
    Jack Chater,Rui-Hua Xu, Diogo Diniz Gomes Bugano,Jen-Shi Chen,Florian Lordick,Scott Paulson,Sun-Young Rha,Josep Tabernero,Kensei Yamaguchi,Jun Zhang, Jacqui Aitchison, Zhouer Sun,

    TPS4204 Background: Patients with GC/GEJC often present with advanced disease, and prognosis for these patients is poor, with a 5-year relative survival rate of ~5%, highlighting a need for new treatment options. HER2 overexpression/amplification occurs in ~20% of cases. Adding immune checkpoint inhibition to trastuzumab (anti-HER2 monoclonal antibody) and chemotherapy has shown clinical benefit in patients with advanced HER2-positive GC/GEJC (Janjigian YY, et al. N Engl J Med 2024), and led to the approval of pembrolizumab (programmed cell death-1 [PD-1] inhibitor), trastuzumab, and chemotherapy for HER2-positive GC/GEJC with programmed cell death ligand-1 combined positive score (PD-L1 CPS) ≥1. T-DXd (a HER2-directed antibody-drug conjugate) is approved for the treatment of patients with locally advanced/metastatic HER2-positive GC/GEJC who have received a prior trastuzumab-based regimen. In addition, dual inhibition of PD-1 or PD-L1 and the immune checkpoint T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) has shown encouraging results across multiple tumor types, without major increases in high-grade toxicity compared with PD-1 or PD-L1 inhibition alone. Rilvegostomig is a monovalent, bispecific, humanized IgG1 monoclonal antibody targeting both PD-1 and TIGIT receptors that has shown encouraging efficacy with manageable safety as monotherapy in non-small-cell lung cancer (Hiltermann TJN, et al. WCLC 2024. Oral presentation 1751) and with chemotherapy in HER2-negative GC/GEJC (Herrero FR, et al. Ann Oncol 2024. Abs 1422P). Methods: ARTEMIDE-Gastric01 (NCT06764875) is a phase 3, randomized, open-label, sponsor-blinded, multicenter, global study that will assess the efficacy and safety of rilvegostomig with T-DXd and chemotherapy as 1L treatment in HER2-positive GC/GEJC with PD-L1 CPS ≥1. Approximately 840 participants (pts) will be randomized to Arm A: rilvegostomig + T-DXd + investigator’s (INV) choice of capecitabine or 5-fluorouracil (5-FU); Arm B: pembrolizumab + trastuzumab + INV choice of 5-FU and cisplatin (FP) or capecitabine and oxaliplatin (CAPOX); Arm C: rilvegostomig + trastuzumab + INV choice of FP or CAPOX. Eligible pts will have previously untreated, unresectable, histologically confirmed, locally advanced/metastatic HER2-positive and PD-L1 CPS ≥1 GC/GEJC and an ECOG performance status of 0 or 1. Dual-primary endpoints are progression-free survival (RECIST v1.1; blinded independent central review) and overall survival in all randomized pts. Secondary endpoints include safety/tolerability, objective response rate, and duration of response. Enrollment is planned across ~25 countries in Asia, Australia, Europe, and North and South America. Clinical trial information: NCT06764875 .

    2026ONCOLOGY RESEARCH AND TREATMENT(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Assessment of Fellowship Didactic Curricula in Hematology/Oncology: Cross-Sectional Findings from the PODCAST-HOF Trial.
    Ronak H. Mistry, Karine Tawagi, Daniel J. Hausrath, Samantha A. Armstrong, Inas A. Abuali, Ankoor N. Biswas,Srijan Valasapalli, Pranali S. Pachika, Moriah K. Forster, Ericson Stoen, Yurhee Lee, Giuliana G. Berardi,

    Didactic lectures play an important role in hematology/oncology fellowship education. How each program structures their curricula is determined independently. To improve the trainee experience, identifying best practices is essential, but limited data about program structure exist. This marks the first cross-sectional analysis of hematology/oncology fellowship didactic curricula from a heterogenous group of programs to-date. Twenty-eight US Accreditation Council for Graduate Medical Education-accredited hematology/oncology fellowship programs were included. Local principal investigators completed a 21-question survey containing a series of multiple-choice and open-ended questions to understand participating programs’ educational curricula and structure. Responses were analyzed using descriptive statistics for multiple-choice questions and thematic analysis for open-ended questions. All participating programs completed the background assessment (100

    2026Journal of Cancer Education(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Outcomes in Children Receiving Single-Fraction Gamma Knife Radiosurgery for Arteriovenous Malformation
    Steven K. Montalvo,Tu Dan, Kimberly Taing,Strahinja Stojadinovic, Kiran A. Kumar,Zabi Wardak, Robert D. Timmerman, Bradley Weprin

    Stereotactic radiosurgery (SRS) is used for arteriovenous malformations (AVM), but the risk for secondary malignancy (SM), radiation necrosis (RN), obliteration rates (ObR), and late neurologic toxicities in pediatric patients is not well defined. To address this, we reviewed our two-decade-long institutional experience treating pediatric AVMs with SRS. Retrospective review of patients receiving single-fraction SRS for AVM between 1/2006 and 12/2023. ObR and RN were determined on neuroimaging, and toxicities by clinical evaluation. Overall follow-up was 56 months (range 6–193); 59 patients had follow-up > 36 months (median 85 months). Eighty-nine patients/101 AVMs were treated at average age of 12.9 years (range 2.36–20.1). Median follow-up was 56 months (range 6–193); 59 patients (66.3

    2026Child's Nervous System(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Abstract PS5-05-09: Treatment Persistence and Dose Modifications in US Patients with HR+, HER2-, Node-Positive, Early Breast Cancer Treated with Adjuvant Abemaciclib
    H. Soliman, S. Dent, A. Liepa, V. Stefaniak, M. Huang, T. Sugihara, K. Moreira, K. Hudson, M. Goetz

    Two years of adjuvant abemaciclib plus endocrine therapy is approved and guideline-recommended in patients (pts) with HR+, HER2-, node-positive, early breast cancer (EBC) at high risk of recurrence. In initial real-world studies, the high rate (>85%) of treatment (tx) persistence beyond 3 months suggests that adjuvant abemaciclib is well-tolerated in routine clinical practice.1,2 Dose reductions were associated with higher persistence in prior studies and clinical trial data have shown that efficacy of abemaciclib was maintained with dose reductions. This study describes 6-month tx persistence and dosing patterns in pts with HR+, HER2-, node-positive EBC initiating abemaciclib 150 mg twice daily (BID). Retrospective data were accessed from the US de-identified Flatiron Health Research Database. Adults with HR+, HER2-, node-positive, EBC, who initiated abemaciclib 150 mg BID from Jan 2022-Jun 2024 were eligible and further characterized by ≥1 vs no dose reduction. Data cut-off was Dec 2024. Persistence rate was the proportion of pts on abemaciclib >6 months, allowing for ≤60-day medication gap within this period. Time to dose modifications and reasons for discontinuation (DC) were summarized. Subgroup analyses were conducted in pts confirmed as meeting the monarchE high-risk criteria (N2, N3, or N1 plus Grade 3 and/or tumor >5 cm). All analyses were descriptive. Of 1063 eligible pts, median age was 56 years (IQR 47, 65). Most had N1 (48%) or N2 (34%) disease. Median follow-up was 17.5 months (IQR 11, 25). Tx persistence at 6 months was 75%. DC was mostly due to adverse events (AEs; 19%) and <1% due to recurrence. Approximately 50% of pts had ≥1 dose reduction. Persistence was 85% in pts with ≥1 dose reduction and 64% in pts with no dose reductions. 70% of pts who DC’d by 6 months did not have a dose reduction. Median time from start of abemaciclib to first dose change and/or hold was 49 days (IQR 23, 111). During the first 30 days of tx and Days 31-90, DCs due to AEs were lower in pts with dose reductions vs pts with no dose reductions (Table). Persistence and use of dose reductions were similar in pts confirmed as meeting the monarchE high-risk criteria. In US clinical practice, a majority (75%) who initiated adjuvant abemaciclib continued abemaciclib beyond 6 months. Tx persistence was higher among pts with dose reductions relative to those with no dose reductions, and rates of early DCs due to AEs were low in pts with dose reductions. Given that dose reductions in monarchE were not associated with reduced efficacy, these additional real-world data support the use of early dose modifications to improve tolerability and tx persistence for adjuvant abemaciclib in pts with high risk of recurrence. H. Soliman, S. Dent, A. Liepa, V. Stefaniak, M. Huang, T. Sugihara, K. Moreira, K. Hudson, M. Goetz. Treatment Persistence and Dose Modifications in US Patients with HR+, HER2-, Node-Positive, Early Breast Cancer Treated with Adjuvant Abemaciclib [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-05-09.

    2026Clinical Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 510 篇论文

    合作机构(100)

    德克萨斯大学奥斯汀分校合作论文 73
    纪念斯隆凯特琳癌症中心合作论文 50
    丹娜—法伯癌症研究所合作论文 44
    US Oncology Network合作论文 31
    Sarah Cannon合作论文 23
    Massachusetts General Hospital,Harvard Medical School合作论文 22
    华盛顿大学合作论文 22
    Rocky Mountain Cancer Centers合作论文 20
    加州大学合作论文 20
    莫菲特癌症中心合作论文 18

    机构统计